EA201170338A1 - Способ и состав для лечения неблагоприятных биологических состояний - Google Patents

Способ и состав для лечения неблагоприятных биологических состояний

Info

Publication number
EA201170338A1
EA201170338A1 EA201170338A EA201170338A EA201170338A1 EA 201170338 A1 EA201170338 A1 EA 201170338A1 EA 201170338 A EA201170338 A EA 201170338A EA 201170338 A EA201170338 A EA 201170338A EA 201170338 A1 EA201170338 A1 EA 201170338A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
biological conditions
composition
adverse biological
presented
Prior art date
Application number
EA201170338A
Other languages
English (en)
Inventor
Раджив Бхушан
Джерри Б. Джин
Амит Госвами
Original Assignee
Лайвайонекс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лайвайонекс Инк. filed Critical Лайвайонекс Инк.
Publication of EA201170338A1 publication Critical patent/EA201170338A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Представлен способ лечения неблагоприятных биологических состояний, где биологически активное средство, такое как биологическая макромолекула, например нуклеиновая кислота или пептидное соединение, вводят нуждающемуся в таком лечении индивидууму в составе, содержащем усилитель транспорта со структурой формулы (I), где Q, Rи Rявляются такими, как определено в настоящем документе. Характерным и предпочтительным усилителем транспорта является метилсульфонилметан (MSM). Также представлены составы.
EA201170338A 2008-08-15 2009-08-17 Способ и состав для лечения неблагоприятных биологических состояний EA201170338A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18906008P 2008-08-15 2008-08-15
PCT/US2009/004709 WO2010019276A2 (en) 2008-08-15 2009-08-17 Method and formulation for treating adverse biological conditions

Publications (1)

Publication Number Publication Date
EA201170338A1 true EA201170338A1 (ru) 2011-10-31

Family

ID=41669540

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170338A EA201170338A1 (ru) 2008-08-15 2009-08-17 Способ и состав для лечения неблагоприятных биологических состояний

Country Status (5)

Country Link
US (1) US20100209419A1 (ru)
EP (1) EP2328570A4 (ru)
AU (1) AU2009282456A1 (ru)
EA (1) EA201170338A1 (ru)
WO (1) WO2010019276A2 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2694758C2 (ru) 2012-12-20 2019-07-16 Раджив Бхушан Антимикробные композиции
US20220047614A1 (en) * 2016-02-25 2022-02-17 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
CN112307562B (zh) * 2020-10-30 2022-03-01 泉州装备制造研究所 综合热变形与重力变形的大型飞机上复杂部件的装配方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0996739A2 (en) * 1998-05-06 2000-05-03 Transgene S.A. Improvments in gene therapy using compositions comprising a polynucleotide and a nuclease inhibitor or interleukin-10
US6403116B1 (en) * 2000-11-03 2002-06-11 Triarco Inductries, Inc. Coenzyme Q10 formulation
EP1539244A1 (en) * 2002-06-27 2005-06-15 Novo Nordisk A/S Use of dimethyl sulfone as isotonicity agent
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US20090053197A1 (en) * 2006-06-14 2009-02-26 Ramaekers Joseph C Transfer Factor Compositions and Methods
CA2678500A1 (en) * 2007-02-15 2008-08-21 Derma-Young Ltd. Compositions and methods for enhancing transmucosal delivery

Also Published As

Publication number Publication date
EP2328570A4 (en) 2012-10-24
WO2010019276A2 (en) 2010-02-18
EP2328570A2 (en) 2011-06-08
US20100209419A1 (en) 2010-08-19
WO2010019276A3 (en) 2010-06-03
AU2009282456A1 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
EA201170772A1 (ru) Органические соединения
GEP20146122B (en) Pharmaceutical composition
UA107174C2 (uk) Кристалічні форми саксагліптину та процес їх одержання (варіанти)
EA201270666A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
EA200601279A1 (ru) Пиперидинилкарбонилпирролидины и их применение в качестве агонистов меланокортина
EA200971104A1 (ru) Производные бензимидазола
MX2009004475A (es) Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
EA201171333A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-с-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
EA201170289A1 (ru) Фармацевтические композиции и способы их получения при низкой концентрации примесей
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
EA201001368A1 (ru) Гетероциклические производные мочевины и способы их применения-211
BRPI0600194A (pt) composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA200801287A1 (ru) Пиримидиновые производные для лечения аномального клеточного роста
EA201270560A1 (ru) Спиропиперидиновые соединения и их фармацевтическое применение для лечения диабета
EA200702593A1 (ru) Высококонцентрированные композиции, применимые для борьбы с экто- и эндопаразитами
TW200611694A (en) Liquid composition for veterinary medicine, process for its preparation and use thereof
EP3020397A3 (en) Process for the manufacture of ajoene derivatives
EA200702375A1 (ru) Производные мочевины, способы их получения и применения
BR112012014721A2 (pt) composição de hormônio do crescimento
EA201001859A1 (ru) Гетероциклические производные мочевины и способы их применеия
ATE493110T1 (de) Kosmetische zusammensetzung zur stimulierung der synthese der proteine der basalmembran
EA201170338A1 (ru) Способ и состав для лечения неблагоприятных биологических состояний
RU2012114820A (ru) Модифицированный эритропоэтин, к которому присоединена водорастворимая длинноцепочечная молекула
BRPI0614434B1 (pt) composição líquida oral compreendendo arginina e ácido r-alfa-lipóico